{"id":"W3087953324","doi":"10.1016/j.annonc.2020.08.710","title":"596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; EMD Serono; Genentech; PharmaMar; Astellas Pharma; Eisai; MacroGenics; Juno Therapeutics; Incyte; Five Prime Therapeutics; bluebird bio; Daiichi Sankyo Europe; Halozyme; Aptitude Health; SymBio Pharmaceuticals Limited; AbbVie; Takeda Oncology; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Radiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008287501,0.001277656,0.002302422,0.0003688266,0.0004148226,0.001429782,0.0008431688,0.001241852,0.006171187],"category_scores_gemma":[0.0004656445,0.0006221075,0.001446966,0.0003198305,0.0009877143,0.00068013,0.0002959715,0.003717708,0.001906251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009112243,"about_ca_system_score_gemma":0.001707211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001904365,"about_ca_topic_score_gemma":0.004279674,"domain_scores_codex":[0.9996154,0.0001329019,0.0000138502,0.0000531997,0.00003168551,0.0001529739],"domain_scores_gemma":[0.9997011,0.0000409718,0.00003168212,0.00003533753,0.00001872659,0.0001721715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6163234,0.1038947,0.004623809,0.001289554,0.002086872,0.0005082163,0.0004053415,0.005079246,0.1263662,0.001221994,0.01612619,0.1220746],"study_design_scores_gemma":[0.419278,0.5474352,0.00814447,0.00004753469,0.0006248725,0.0003603361,0.000112475,0.001837755,0.01225838,0.0003965301,0.009439911,0.00006442579],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843427,0.003844463,0.0008814973,0.0008146747,0.0005221338,0.002330371,0.002925939,0.0002077303,0.004130472],"genre_scores_gemma":[0.9791694,0.003011109,0.00216319,0.001210345,0.0002120976,0.002153761,0.004871082,0.00008004469,0.007128919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006171187,"threshold_uncertainty_score":0.02064472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05534409063387729,"score_gpt":0.4102253372847152,"score_spread":0.3548812466508379,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}